PL3618875T3 - Terapia skojarzona obejmująca inhibitor raf i trametynib - Google Patents

Terapia skojarzona obejmująca inhibitor raf i trametynib

Info

Publication number
PL3618875T3
PL3618875T3 PL18726224.1T PL18726224T PL3618875T3 PL 3618875 T3 PL3618875 T3 PL 3618875T3 PL 18726224 T PL18726224 T PL 18726224T PL 3618875 T3 PL3618875 T3 PL 3618875T3
Authority
PL
Poland
Prior art keywords
trametinib
combination therapy
raf inhibitor
raf
inhibitor
Prior art date
Application number
PL18726224.1T
Other languages
English (en)
Inventor
Vesselina COOKE
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3618875(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3618875T3 publication Critical patent/PL3618875T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
PL18726224.1T 2017-05-02 2018-04-30 Terapia skojarzona obejmująca inhibitor raf i trametynib PL3618875T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en) 2017-05-02 2018-04-30 Combination therapy

Publications (1)

Publication Number Publication Date
PL3618875T3 true PL3618875T3 (pl) 2023-10-23

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18726224.1T PL3618875T3 (pl) 2017-05-02 2018-04-30 Terapia skojarzona obejmująca inhibitor raf i trametynib

Country Status (17)

Country Link
US (2) US11266653B2 (pl)
EP (2) EP3618875B1 (pl)
JP (3) JP7309614B2 (pl)
KR (2) KR102641827B1 (pl)
CN (1) CN110494166B (pl)
AU (1) AU2018262891B2 (pl)
CA (1) CA3057969A1 (pl)
CL (1) CL2019003091A1 (pl)
DK (1) DK3618875T3 (pl)
ES (1) ES2952265T3 (pl)
FI (1) FI3618875T3 (pl)
IL (2) IL311471A (pl)
MX (1) MX393855B (pl)
PL (1) PL3618875T3 (pl)
PT (1) PT3618875T (pl)
TW (1) TWI798218B (pl)
WO (1) WO2018203219A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973829B2 (en) 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
IL311471A (en) * 2017-05-02 2024-05-01 Novartis Ag Combination therapy
US20200237764A1 (en) * 2017-08-11 2020-07-30 Curematch, Inc. Drug combinations for targeting multiple mutations in cancer
KR20210105388A (ko) 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
EP4106756A1 (en) * 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
CA3151403A1 (en) * 2020-02-27 2021-09-02 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
JP2023525100A (ja) * 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202227088A (zh) * 2020-08-31 2022-07-16 瑞士商諾華公司 組合療法
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
AU2023227427A1 (en) 2022-03-02 2024-09-19 Novartis Ag Precision therapy for the treatment of cancer
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
CN117919235A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗kras突变相关疾病的用途
WO2024088275A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗耐药性肿瘤的用途
EP4704850A1 (en) 2023-05-04 2026-03-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0923579A1 (en) 1996-08-27 1999-06-23 Novartis AG Herbicidal s-substituted 1,2,4,6-thiatriazines
WO1998038984A2 (en) 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU4798000A (en) 1999-04-09 2000-11-14 Smithkline Beecham Corporation Triarylimidazoles
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
DE60015594T2 (de) 1999-11-22 2005-10-27 Smithkline Beecham P.L.C., Brentford Imidazolderivate und deren verwendung als raf kinase inhibitoren
EP1251849A1 (en) 2000-01-18 2002-10-30 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
MXPA02007134A (es) 2000-01-18 2003-03-27 Vertex Pharma Inhibidores de girasa y usos de los mismos.
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
US7235658B2 (en) 2000-03-06 2007-06-26 Smithkline Beecham P.L.C. Imidazol derivatives as Raf kinase inhibitors
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
AP2001002217A0 (en) 2000-07-19 2001-09-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US20040053943A1 (en) 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
ATE341539T1 (de) 2001-01-26 2006-10-15 Chugai Pharmaceutical Co Ltd Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2004016597A2 (en) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
DE60328028D1 (de) 2002-09-18 2009-07-30 Pfizer Prod Inc Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CA2556944C (en) 2004-03-05 2012-10-09 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
EP1894932A1 (en) 2004-06-11 2008-03-05 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2006026306A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
WO2007118149A2 (en) 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
JP4450857B2 (ja) 2006-08-08 2010-04-14 中外製薬株式会社 Ｐｉ３ｋ阻害剤としてのピリミジン誘導体およびその用途
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
UA98961C2 (uk) 2007-06-27 2012-07-10 Астразенека Аб Похідні піразинону та їх застосування у лікуванні легеневих захворювань
US7968536B2 (en) 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
EP2178866A2 (en) 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
CA2693967A1 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
UY31322A1 (es) 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
KR101408517B1 (ko) 2008-03-21 2014-06-17 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0915205A2 (pt) 2008-06-11 2017-03-21 Dana Farber Cancer Inst Inc compostos e composições úteis para o tratamento de malária
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
NZ591176A (en) 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2771563A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
EP2498608A4 (en) 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
EP2520575B1 (en) 2009-12-28 2016-11-30 General Incorporated Association Pharma Valley Project Supporting Organisation 1,3,4-oxadiazole-2-carboxamide compound
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
WO2012125981A2 (en) 2011-03-17 2012-09-20 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
BR112014004560A2 (pt) 2011-09-01 2017-04-04 Irm Llc compostos e composições como inibidores de c-kit quinase
BR112014006743A8 (pt) 2011-09-21 2018-01-09 Cellzome Ltd composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
KR20150020169A (ko) 2012-05-15 2015-02-25 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
AR091654A1 (es) 2012-07-02 2015-02-18 Biogen Idec Inc COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
TR201904980T4 (tr) 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EP2892535B1 (en) * 2012-09-04 2021-09-22 Novartis AG Method of adjuvant cancer treatment
CN105102456B (zh) 2012-09-28 2017-11-14 癌症研究技术有限公司 非典型蛋白激酶c的氮杂喹唑啉抑制剂
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SI2976106T1 (sl) 2013-03-21 2021-08-31 Array Biopharma Inc. Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec
SG11201601467SA (en) 2013-11-01 2016-05-30 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
AU2014368906B2 (en) 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107001329B (zh) 2014-09-12 2020-09-01 诺华股份有限公司 作为激酶抑制剂的化合物和组合物
US10167279B2 (en) 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
EP4119559A1 (en) 2015-04-15 2023-01-18 BeiGene, Ltd. Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
KR20180033523A (ko) 2015-07-10 2018-04-03 젠맵 에이/에스 암 치료를 위한 axl-특이적 항체-약물 접합체
WO2017037575A1 (en) 2015-08-28 2017-03-09 Novartis Ag A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
JP2018525425A (ja) 2015-08-28 2018-09-06 ノバルティス アーゲー がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
KR102439911B1 (ko) 2016-06-03 2022-09-05 어레이 바이오파마 인크. 제약학적 복합제제
BR112018075371A2 (pt) 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
US10973829B2 (en) 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
US11590133B2 (en) 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combination therapy
WO2018213302A1 (en) 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
TW202023556A (zh) 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
KR20210105388A (ko) 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
EP4106756A1 (en) 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
TW202227088A (zh) 2020-08-31 2022-07-16 瑞士商諾華公司 組合療法

Also Published As

Publication number Publication date
CN110494166B (zh) 2022-11-08
CN110494166A (zh) 2019-11-22
PT3618875T (pt) 2023-08-07
IL270224A (pl) 2019-12-31
JP2024160223A (ja) 2024-11-13
IL270224B1 (en) 2024-04-01
EP3618875A1 (en) 2020-03-11
MX393855B (es) 2025-03-21
BR112019022511A2 (pt) 2020-05-12
ES2952265T3 (es) 2023-10-30
WO2018203219A1 (en) 2018-11-08
KR102641827B1 (ko) 2024-03-04
US20200246346A1 (en) 2020-08-06
IL311471A (en) 2024-05-01
MX2019012884A (es) 2020-01-14
EP3618875B1 (en) 2023-04-05
JP2020518568A (ja) 2020-06-25
CA3057969A1 (en) 2018-11-08
JP7520189B2 (ja) 2024-07-22
KR20190141164A (ko) 2019-12-23
US12036227B2 (en) 2024-07-16
DK3618875T3 (da) 2023-07-10
RU2019134757A3 (pl) 2021-08-17
AU2018262891B2 (en) 2021-04-01
EP4272740A1 (en) 2023-11-08
US11266653B2 (en) 2022-03-08
JP7309614B2 (ja) 2023-07-18
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
FI3618875T3 (fi) 2023-07-04
US20220143036A1 (en) 2022-05-12
CL2019003091A1 (es) 2020-02-07
JP2023145467A (ja) 2023-10-11
AU2018262891A1 (en) 2019-10-17
RU2019134757A (ru) 2021-06-02
TWI798218B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
PL3618875T3 (pl) Terapia skojarzona obejmująca inhibitor raf i trametynib
IL264931B (en) Medicinal combinations containing a raf inhibitor and an erk inhibitor
PL3256218T3 (pl) Inhibitor kdm1a i jego zastosowanie w terapii
IL267925B (en) hsd17b13 variants and their uses
IL244468A0 (en) A device for physical therapy and training
IL262378A (en) Compositions and methods containing a capsid assembly inhibitor
GB201707153D0 (en) Therapy
ZA201606349B (en) Radiotherapy board and couch
PT3582838T (pt) Inaladores e métodos relacionados
SI3621694T1 (sl) Zaviralci lrrc33 in njihove uporabe
GB201708663D0 (en) Therapy
GB201719646D0 (en) Therapy
PT3582839T (pt) Inalador
LT3532459T (lt) Lsd1 inhibitoriai ir jų medicininis panaudojimas
IL261505A (en) Combined treatment using liv1-adc and a chemotherapeutic agent
GB201715194D0 (en) Compounds and their therapeutic use
ZA201906258B (en) Therapeutic compounds and methods
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
PT3582837T (pt) Inaladores
IL253287A0 (en) Combination therapy using cd19-adc and vincristine
GB201700526D0 (en) Therapeutic use
HK40018051A (en) Combination therapy comprising a raf inhibitor and trametinib
HK40018051B (en) Combination therapy comprising a raf inhibitor and trametinib
PL3354163T3 (pl) Materac przenośny
GB201820761D0 (en) Defibrillator status indication and activation